Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1973 Aug;14(4):509-14.

Circulating conversion products of C3 in liver disease. Evidence for in vivo activation of the complement system

Circulating conversion products of C3 in liver disease. Evidence for in vivo activation of the complement system

P Teisberg et al. Clin Exp Immunol. 1973 Aug.

Abstract

Circulating conversion products of the third component of human complement (C3) were sought for in different forms of liver disease by the method of antigen–antibody crossed electrophoresis. Immunochemical determinations of C3 and C4 by the single radial immunodiffusion method were performed simultaneously.

The conversion product C3b was found in four out of twelve patients with chronic active hepatitis (CAH) and in seven out of nine with primary biliary cirrhosis (PBC). C3b was also seen in a patient with the special form of acute hepatitis characterized by arthritic prodromas and a high titre of hepatitis-associated antigen (HAA) in serum in the acute phase.

The group of CAH patients had low serum C3 and C4 regardless of whether C3 breakdown products could be demonstrated or not. In PBC normal serum levels of C3 and C4 were generally found.

It is concluded that in some patients with CAH and in a majority of the patients with PBC activation of complement takes place in vivo, possibly on immune complexes deposited in the liver. The serum level of C3 is not a good parameter of immunologic activity in liver disease.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Immunochemistry. 1965 Sep;2(3):235-54 - PubMed
    1. Immunology. 1967 Mar;12(3):313-9 - PubMed
    1. J Clin Invest. 1967 Dec;46(12):2021-34 - PubMed
    1. Lancet. 1968 Sep 14;2(7568):626-8 - PubMed
    1. J Clin Invest. 1969 Nov;47(11):2469-84 - PubMed

Substances

LinkOut - more resources